FDA Considers Forecasting Tools in Clinical Trial Reform Efforts

The FDA and HHS have introduced Operation TrialBlazer, a broad initiative designed to update and streamline the process of clinical drug development in the United States.

As part of this initiative, the FDA began seeking public input on a pilot program that aims to decrease the time required to move from drug identification to the start of Phase 1 human trials, with the goal of reducing early-stage trial timelines by six to twelve months.

On September 15, 2026, the FDA started accepting applications for its Expedited IND Pilot Program, which is intended to help companies begin human testing of new drugs more rapidly. The program includes rolling review of investigational new drug (IND) submission components and coordination with institutional review boards (IRBs) and trial site activation processes.

The FDA’s Sentinel System plays a role in monitoring the safety of medical products by analyzing large-scale healthcare data. This system currently includes active data from approximately 63.3 million patients and has been used in numerous medical product evaluations.

What the numbers show

• Operation TrialBlazer was launched on June 22, 2026.
• Applications for the Expedited IND Pilot Program opened on September 15, 2026.
• The Sentinel System covers about 63.3 million patients.

Josh Morrison, who serves as co-founder and President of the advocacy group 1Day Sooner, has proposed that the FDA could add forecasting methods, potentially using artificial intelligence, to its decision-making processes. He stated that these forecasts could initially provide quantitative predictions, such as estimated risks or potential side effects, alongside current review procedures.

Morrison further suggested that, in the future, reliable forecasting systems might serve as legal triggers in regulatory decisions. For example, a system predicting a high benefit-to-risk ratio could automatically prompt approval, according to his published proposal.

Operation TrialBlazer and the related pilot programs reflect ongoing efforts by federal agencies to modernize clinical trial frameworks and incorporate new tools for evaluating drug safety and efficacy. The FDA continues to gather feedback from stakeholders on these proposed changes and pilot initiatives.

1Day Sooner, the group led by Morrison, focuses on advocating for reforms in clinical trial processes. The organization has highlighted the potential for new technologies to improve both the speed and quality of drug development oversight.

* This article is based on publicly available information at the time of writing.